QQ交談
您所在位置：請輸入產品關鍵字：
郵編：200431
聯系人：王小姐
電話：021-56640936
傳真：021-33250231
手機：13122441390 15900755943
留言：發送留言
個性化：www.shifengsj.com
網址：www.shfeng-edu.com
商鋪：http://www.grannyfreesex.com/st236594/
上海士鋒生物關于五個LOH亞區域的推廣
點擊次數：1161 發布時間：2013-6-10
Identification of novel subregions of LOH in gastric cancer and analysis of the HIC1 and TOB1 tumor suppressor genes in these subregions.
Yu Jingcui J,Liu Peng P,Cui Xiaobo X,Sui Yu Y,Ji Guohua G,Guan Rongwei R,Sun Donglin D,Ji Wei W,Liu Fangli F,Liu An A,Zhao Yuzhen Y,Yu Yang Y,Jin Yan Y,Bai Jing J,Geng Jingshu J,Xue Yingwei Y,Qi Jiping J,Lee Ki-Young KY,Fu Songbin S,
Previously, we identified 3 overlapping regions showing loss of heterozygosity （LOH, R（1）-R（3） from 11 to 30 cM） on chromosome 17 in 45 primary gastric cancers （GCs）. The data indicated the presence of tumor suppressor genes （TSGs） on chromosome 17 involved in GC. Among the putative TSGs in these regions, HIC1 （in SR（1）） and TOB1 （in SR（3）） remain to be examined in GC. By immunohistochemistry （IHC）, methylation-specific PCR （MSP） and western blot, we evaluated the expression and regulation status for HIC1 and TOB1 protein in GC. We narrowed down the deletion intervals on chromosome 17 and defined five smaller LOH subregions, SR（1）-SR（5） （0.54 to 3.42 cM）, in GC. We found that HIC1 had downregulated expression in 86% （91/106） and was methylated in 87% （26/30） of primary GCs. Of the primary GCs showing downregulation of HIC1 protein, 75% （18/24） had methylated HIC1 gene. TOB1 was either absent or expressed at reduced levels in 75% （73/97） of the GC samples. In addition, a general reduction was found in total and the ratio of unphosphorylated to phosphorylated TOB1 protein levels in the differentiated GC cell lines. Further analysis revealed significant simultaneous downregulation of both HIC1 and TOB1 protein in GC tissue microarray samples （67%, 52/78） and in primary GCs （65%, 11/17）. These results indicate that silencing of HIC1 and TOB1 expression is a common occurrence in GC and may contribute to the development and progression of the disease.